

**INFORMATION DISCLOSURE STATEMENT**

Applicants : Kiyohiko, et al.  
App. No. : 10/564,302  
Filed : January 10, 2006  
For : DRUG FOR CANCER THERAPY  
Examiner : Sheela Jitendra Huff  
Art Unit : 1643  
Conf. No. : 7332

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing three (3) and enclosing two (2) references to be considered by the Examiner.

U.S. Patent No. 5,317,084 is the U.S. counterpart to JP5-238948A.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Aug 4, 25, 2007

By: Che S. Chereskin

Che Swyden Chereskin, Ph.D.  
Registration No. 41,466  
Agent of Record  
Customer No. 20,995  
(949) 760-0404